A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). (CROSSWALK-a)

A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)

The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD. The primary objective of this study is safety and will additionally evaluate pharmacokinetics (how crovalimab is processed by your body), pharmacodynamics (how your body reacts to crovalimab) and the preliminary efficacy of crovalimab compared with placebo.

Study Overview

• Status: Completed
• Conditions: Sickle Cell Disease
• Intervention / Treatment: Drug: Crovalimab; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• Brazil
  • Estado de Bahia
    • Salvador, Estado de Bahia, Brazil, 41253-190
      • Hospital Sao Rafael - HSR
  • Rio Grande do Sul
    • Porto Alegre, Rio Grande do Sul, Brazil
      • Hospital das Clinicas - UFRGS
• France
  • Créteil, France, 64010
    • CHU Henri Mondor
• Italy
  • Veneto
    • Verona, Veneto, Italy, 37134
      • Azienda Ospedaliera di Verona-Policlinico G.B. Rossi
• Kenya
  • Eldoret, Kenya, 30100
    • International Cancer Institute (ICI)
  • Nairobi, Kenya
    • Gertrude's Children Hospital
• Lebanon
  • Beirut, Lebanon, 1107 2020
    • American University of Beirut - Medical Center
  • Tripoli, Lebanon
    • Hopital Nini
• Netherlands
  • Amsterdam, Netherlands, 1081 HV
    • Amsterdam UMC location VUmc
• South Africa
  • Johannesburg, South Africa, 2193
    • Charlotte Maxeke Johannesburg Hospital
• Spain
  • Madrid, Spain, 28009
    • Hospital General Univ. Gregorio Maranon
  • Seville, Spain, 41013
    • Hospital Universitario Virgen del Rocio
  • Zaragoza, Spain, 50009
    • Hospital Universitario Miguel Servet
• United Kingdom
  • London, United Kingdom, W12 OHS
    • Hammersmith Hospital
• United States
  • Georgia
    • Atlanta, Georgia, United States, 30329
      • Children's Healthcare of Atlanta
  • New York
    • New York, New York, United States, 10029
      • Icahn School of Medicine at Mount Sinai

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 55 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Body weight >=40 kg.
• Confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia) or HbSβ0 (SCD genotype of sickle cell beta zero thalassemia).
• Vaccination against Neisseria Meningitidis serotypes A, C, W, and Y.
• Vaccinations against H. influenzae type B and S. pneumoniae.
• Participants vaccinated against SARS-CoV-2 are eligible, as long as it has been 3 days or more after inoculation with the vaccine.
• Diagnosis of an acute uncomplicated VOE, that requires admission to a hospital/acute medical facility and treatment with parenteral opioid analgesics.
• Adequate hepatic and renal function.
• Hemoglobin >=5 grams/deciliter (g/dL)
• Platelet count >=100,000/microliter (µL)
• Participants receiving SCD-directed therapies must be on a stable dose for >=28 days.
• For female participants of childbearing potential, an agreement to remain abstinent or use contraception for 322 days (approximately 10.5 months) after the dose of study treatment.

Exclusion Criteria:

• More than 10 VOEs within the last 12 months prior to presentation, that have required a medical facility visit.
• Pain related to the current VOE ongoing for >36 hours.
• Acute pain related to avascular necrosis, hepatic or splenic sequestration, or priapism.
• Pain atypical of an acute uncomplicated VOE.
• Evidence of or suspicion of ACS.
• Evidence or high suspicion of a severe systemic infection.
• Major surgery and/or hospitalization for any reason within 30 days.
• History of Neisseria meningitidis infection within 6 months prior.
• Known HIV infection with a documented CD4 count <200 cells/µL.
• Transfusion or receipt of blood products within 3 months or current participation in a chronic transfusion protocol.
• Immunized with a live attenuated vaccine within 30 days.
• History of hematopoietic stem cell transplant.
• Known or suspected hereditary complement deficiency.
• Pregnant or breastfeeding, or intending to become pregnant during the study or within 322 days (approximately 10.5 months) after the study drug administration.
• Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within the prior 28 days or within five half-lives of that investigational product, whichever was greater.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Crovalimab; Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.	Drug: Crovalimab; Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight >=100 kg).
Placebo Comparator: Placebo; Participants will receive a single IV infusion of matching Placebo.	Drug: Placebo; Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants with Infusion-Related Reactions and Hypersensitivity	Baseline up to Day 84
Percentage of Participants With Adverse Events (AEs)	Baseline up to Day 84

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants with Anti-Drug Antibodies to Crovalimab		Baseline up to Day 84
Time to Improvement of the Primary Acute Uncomplicated VOE From Baseline		Baseline up to Day 84
Total Cumulative Opioid Dose From Baseline		Baseline up to Day 84
Time to Discontinuation of all Parenteral Opioids From Baseline		Baseline up to Day 84
Time to Readiness For Hospital Discharge From Baseline		Baseline up to Day 84
Time to Hospital Discharge From Baseline		Baseline up to Day 84
Time to a Confirmed Decrease in Pain Score of at Least 2 Points From the Maximal Pre-dose Pain Score		Baseline up to Day 84
Change in Pain Score From the Maximal Pre-dose Pain Score to the Score at Hospital Discharge		Baseline up to Day 84
Percentage of Participants who Develop Acute Chest Syndrome (ACS)		Baseline up to Day 28
Percentage of Participants Requiring Intensive Care Unit (ICU)/Critical Care Admission for SCD-related Complications		Baseline up to Day 84
Percentage of Participants Requiring Blood Transfusion for SCD-related Complications		Baseline up to Day 84
Readmission Rate for a VOE or VOE-related Event Within 28 days of Discharge of the Primary Acute Uncomplicated VOE		Baseline up to Day 84
Serum Concentrations of Crovalimab Over Time		Baseline up to Day 84
Change in PD Biomarkers Including Complement Activity (CH50) Over Time	Assessed by a Liposome Immunoassay (LIA)	Baseline up to Day 84
Change Over Time in Free C5 Concentration		Baseline up to Day 84
Change Over Time in Soluble Complement 5b 9 (sC5b-9) Concentration		Baseline up to Day 84

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start (Actual): March 26, 2022
• Primary Completion (Actual): December 23, 2024
• Study Completion (Actual): August 15, 2025

Study Registration Dates

• First Submitted: June 2, 2021
• First Submitted That Met QC Criteria: June 2, 2021
• First Posted (Actual): June 3, 2021

Study Record Updates

• Last Update Posted (Estimated): August 26, 2025
• Last Update Submitted That Met QC Criteria: August 25, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Vaso-occlusive episodes; Pain crisis
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Hematologic Diseases; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hemoglobinopathies; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases; Anemia, Sickle Cell; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs
• Other Study ID Numbers: BO42452; 2020-004840-27 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No